PDCD1 and head and neck squamous cell carcinoma: Recent approval of anti‐programmed cell‐death protein 1 (PD‐1) immunotherapeutic agents such as pembrolizumab and nivolumab has further advanced the treatment of patients with recurrent or metastatic HNSCC [8, 9].